tafetinib structure
|
Common Name | tafetinib | ||
---|---|---|---|---|
CAS Number | 1032265-57-8 | Molecular Weight | 424.51 | |
Density | 1.251±0.06 g/cm3(Predicted) | Boiling Point | 618.2±55.0 °C(Predicted) | |
Molecular Formula | C24H29FN4O2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of tafetinibTafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis[1]. |
Name | tafetinib |
---|---|
Synonym | More Synonyms |
Description | Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis[1]. |
---|---|
Related Catalog | |
References |
Density | 1.251±0.06 g/cm3(Predicted) |
---|---|
Boiling Point | 618.2±55.0 °C(Predicted) |
Molecular Formula | C24H29FN4O2 |
Molecular Weight | 424.51 |
SIM-010603 |
SIM010603 |